Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q3 2019 · 10-Q
Revenue—
Net Income-$29.88M-$29.88MN/M vs Q3 2018 EPS Diluted-$0.51-$0.51N/M vs Q3 2018 Operating Income-$8,855,000N/M Operating Cash Flowderived-$1,126,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
Free Cash Flowderived-$1,126,000N/M ended Sep 30, 2019 · filed Nov 14, 2019 · 45 d after period end